Alexander J. Szubert

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Andy C. Rawstron, J. A. Child, Ruth M. de Tute et al. · Journal of Clinical Oncology · 2013 · 406 citations

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

Kevin Boyd, F. M. Ross, Laura Chiecchio et al. · Leukemia · 2011 · 344 citations · Full text

Hematological Malignancy, Novel Prognostic Model, Medicine +9

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

Gareth J. Morgan, Walter M. Gregory, Faith E. Davies et al. · Blood · 2011 · 329 citations

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory et al. · Blood · 2011 · 192 citations · Full text

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

Guy Thwaites, Matthew Scarborough, Alexander J. Szubert et al. · The Lancet · 2017 · 183 citations · Full text